Unnamed: 0,title,date,stock,sentiment
1225810.0,TG Therapeutics Announces Final Results Of Leukemia Trial At ASCO,2020-05-29 08:28:00-04:00,TGTX,neutral
1225811.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,TGTX,positive
1225812.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,TGTX,neutral
1225813.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,TGTX,positive
1225814.0,TG Therapeutics shares are trading higher after B. Riley FBR maintained its Buy rating on the stock and raised its price target from $29 to $37 per share.,2020-05-18 08:16:00-04:00,TGTX,positive
1225815.0,"B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to $37",2020-05-18 08:04:00-04:00,TGTX,neutral
1225816.0,"The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO",2020-05-15 07:49:00-04:00,TGTX,negative
1225817.0,TG Therapeutics shares are trading lower after the company announced a common stock offering of 8.5 million shares at $18 per share.,2020-05-15 07:09:00-04:00,TGTX,positive
1225818.0,TG Therapeutics Prices Upsized 8.5M Share Public Offering of Common Stock @$18/Share,2020-05-15 05:29:00-04:00,TGTX,positive
1225819.0,"5 Stocks To Watch For May 15, 2020",2020-05-15 04:09:00-04:00,TGTX,neutral
1225820.0,TG Therapeutics Announces Proposed Public Offering of 6M Shares Of Common Stock,2020-05-14 16:07:00-04:00,TGTX,positive
1225821.0,"TG Therapeutics Highlights Data Presentations At ASCO May 29-31, European Hematology Association Congress Jun. 11-14",2020-05-14 09:30:00-04:00,TGTX,neutral
1225822.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,TGTX,neutral
1225823.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,TGTX,neutral
1225824.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,TGTX,negative
1225825.0,"TG Therapeutics Q1 EPS $(0.480) Down From $(0.430) YoY, Sales $38.000K, Same YoY",2020-05-11 16:01:00-04:00,TGTX,neutral
1225826.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,TGTX,negative
1225827.0,66 Biggest Movers From Yesterday,2020-05-07 05:52:00-04:00,TGTX,neutral
1225828.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-06 13:19:00-04:00,TGTX,neutral
1225829.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,TGTX,neutral
1225830.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,TGTX,positive
1225831.0,"B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to $29",2020-05-06 07:58:00-04:00,TGTX,neutral
1225832.0,19 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-05-06 07:36:00-04:00,TGTX,neutral
1225833.0,TG Therapeutics shares are trading higher after the company reported it has raised approximately $60 million in gross proceeds through its at-the-market offering.,2020-05-06 07:28:00-04:00,TGTX,negative
1225834.0,TG Therapeutics Reports Raised $60M In Gross Proceeds From At-The-Market Offering,2020-05-06 07:08:00-04:00,TGTX,negative
1225835.0,"Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $35",2020-05-06 06:31:00-04:00,TGTX,negative
1225836.0,70 Biggest Movers From Yesterday,2020-05-06 05:26:00-04:00,TGTX,neutral
1225837.0,51 Stocks Moving In Tuesday's Mid-Day Session,2020-05-05 12:22:00-04:00,TGTX,neutral
1225838.0,"HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $32",2020-05-05 12:14:00-04:00,TGTX,neutral
1225839.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,TGTX,neutral
1225840.0,TG Therapeutics shares are trading higher after the company announced the results from its UNITY-CLL Phase 3 study for patients with Chronic Lymphocytic Leukemia met its primary endpoint.,2020-05-05 07:45:00-04:00,TGTX,positive
1225841.0,TG Therapeutics Announces Topline Results From UNITY-CLL Phase 3 Study Evaluating Combination Of Umbralisib And Ublituximab For Patients With Chronic Lymphocytic Leukemia; Trial Met Primary Endpoint,2020-05-05 07:18:00-04:00,TGTX,neutral
1225842.0,TG Therapeutics Highlights Publication Of Ublituximab Phase 2 Trials Results In Multiple Sclerosis Journal: Says Was Generally Well Tolerated,2020-05-01 07:31:00-04:00,TGTX,positive
1225843.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 11:47:00-04:00,TGTX,positive
1225844.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,TGTX,negative
1225845.0,TG Therapeutics Reports Orphan Drug Designation For Umbralisib For Treatment Of Follicular Lymphoma,2020-03-05 11:00:00-05:00,TGTX,neutral
1225846.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,TGTX,positive
1225847.0,"TG Therapeutics Q4 EPS $(0.44) Up From $(0.68) YoY, Sales $38K, Same YoY",2020-03-03 07:32:00-05:00,TGTX,neutral
1225848.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,TGTX,neutral
1225849.0,24 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-26 08:01:00-05:00,TGTX,neutral
1225850.0,44 Stocks Moving in Wednesday's Pre-Market Session,2020-02-26 07:20:00-05:00,TGTX,neutral
1225851.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,TGTX,negative
1225852.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-18 11:03:00-05:00,TGTX,neutral
1225853.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,TGTX,neutral
1225854.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-14 07:46:00-05:00,TGTX,neutral
1225855.0,9 Biotechnology Stocks Moving In Friday's Pre-Market Session,2020-02-14 07:36:00-05:00,TGTX,neutral
1225856.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,TGTX,neutral
1225857.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,TGTX,positive
1225858.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,TGTX,negative
1225859.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,TGTX,neutral
1225860.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,TGTX,neutral
1225861.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,TGTX,neutral
1225862.0,TG Therapeutics Option Alert: Feb 21 $19 Calls Sweep (2) above Ask!: 2189 @ $0.276 vs 3922 OI; Earnings 2/28 Before Open [est] Ref=$13.43,2020-01-23 10:26:00-05:00,TGTX,positive
1225863.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,TGTX,neutral
1225864.0,"H.C. Wainwright Maintains Buy on TG Therapeutics, Raises Price Target to $24",2020-01-17 08:59:00-05:00,TGTX,neutral
1225865.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,TGTX,negative
1225866.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,TGTX,neutral
1225867.0,TG Therapeutics Reports Initiation Of Rolling Submission Of New Drug Application To FDA For Umbralisib As Treatment For Patients Previously Treated With Marginal Zone Lymphoma Or Follicular Lymphoma,2020-01-16 07:33:00-05:00,TGTX,neutral
1225868.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,TGTX,neutral
1225869.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,TGTX,neutral
1225870.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,TGTX,negative
1225871.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,TGTX,neutral
1225872.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,TGTX,positive
1225873.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,TGTX,neutral
1225874.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,TGTX,positive
1225875.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,TGTX,positive
1225876.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,TGTX,neutral
1225877.0,31 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-27 08:13:00-05:00,TGTX,neutral
1225878.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,TGTX,neutral
1225879.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,TGTX,negative
1225880.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,TGTX,negative
1225881.0,TG Therapeutics Announces $50M Registered Direct Offering at $9.20/Share,2019-12-23 07:32:00-05:00,TGTX,neutral
1225882.0,58 Biggest Movers From Friday,2019-12-16 05:49:00-05:00,TGTX,neutral
1225883.0,36 Stocks Moving In Friday's Mid-Day Session,2019-12-13 12:41:00-05:00,TGTX,neutral
1225884.0,Stocks That Hit 52-Week Highs On Friday,2019-12-13 11:19:00-05:00,TGTX,neutral
1225885.0,TG Therapeutics shares are trading higher on seemingly no company-specific news.,2019-12-13 10:44:00-05:00,TGTX,neutral
1225886.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,TGTX,negative
1225887.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,TGTX,neutral
1225888.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,TGTX,positive
1225889.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,TGTX,neutral
1225890.0,5 Stocks Moving On ASH Presentations,2019-12-09 14:46:00-05:00,TGTX,neutral
1225891.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,TGTX,neutral
1225892.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,TGTX,neutral
1225893.0,20 Stocks Moving In Monday's Pre-Market Session,2019-12-09 07:49:00-05:00,TGTX,neutral
1225894.0,TG Therapeutics shares are trading higher after the company announced a 100% overall response rate in its phase 1/2 study of ublituximab.,2019-12-09 07:30:00-05:00,TGTX,positive
1225895.0,TG Therapeutics Announces 100% Overall Response Rate in Relapsed/Refractory CLL Patients Treated With U2 (Umbralisib + Ublituximab) Plus Venetoclax at Cycle 7 (N=13) at ASH 2019,2019-12-08 09:19:00-05:00,TGTX,neutral
1225896.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,TGTX,positive
1225897.0,35 Stocks Moving In Friday's Mid-Day Session,2019-11-29 11:40:00-05:00,TGTX,neutral
1225898.0,TG Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-11-29 10:42:00-05:00,TGTX,positive
1225899.0,"Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Lowers Price Target to $19",2019-11-14 13:28:00-05:00,TGTX,negative
1225900.0,TG Therapeutics Q3 EPS $(0.69) May Not Compare To $(0.34) Estimate,2019-11-12 07:38:00-05:00,TGTX,neutral
1225901.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,TGTX,neutral
1225902.0,40 Stocks Moving In Monday's Mid-Day Session,2019-10-28 12:55:00-04:00,TGTX,neutral
1225903.0,TG Therapeutics shares are trading higher after the company announced Phase 2b pivotal trial met its primary endpoint.,2019-10-28 10:29:00-04:00,TGTX,positive
1225904.0,28 Stocks Moving in Monday's Pre-Market Session,2019-10-28 08:05:00-04:00,TGTX,neutral
1225905.0,TG Therapeutics' Phase 2b Pivotal Trial Met its Primary Endpoint,2019-10-28 07:08:00-04:00,TGTX,neutral
1225906.0,TG Therapeutics Announces Final Long-Term Results From Phase 3 GENUINE Study Of  Ublituximab In Combination With Ibrutinib In Patients With High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia,2019-10-24 07:35:00-04:00,TGTX,neutral
1225907.0,TG Therapeutics Option Alert: Nov 15 $5 Calls Sweep (2) near the Ask: 931 @ $0.676 vs 233 OI; Earnings 11/8 Before Open [est] Ref=$5.365,2019-10-16 12:19:00-04:00,TGTX,positive
1225908.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,TGTX,negative
1225909.0,TG Therapeutics Announces Publication of Clinical Data From the Phase I/Ib Combination Trial of Ublituximab and Umbralisib in a Medical Journal,2019-09-30 07:32:00-04:00,TGTX,neutral
1225910.0,52 Biggest Movers From Friday,2019-09-30 03:39:00-04:00,TGTX,neutral
1225911.0,34 Stocks Moving In Friday's Mid-Day Session,2019-09-27 12:11:00-04:00,TGTX,neutral
1225912.0,TG Therapeutics shares are trading higher on seemingly no company-specific news.,2019-09-27 11:58:00-04:00,TGTX,neutral
1225913.0,"The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study",2019-09-12 07:38:00-04:00,TGTX,negative
1225914.0,TG Therapeutics Highlights Presentation Of Data For Ublituximab At European Committee for Treatment and Research in Multiple Sclerosis,2019-09-12 07:35:00-04:00,TGTX,neutral
1225915.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,TGTX,neutral
1225916.0,TG Therapeutics Files To Withdraw Registration Statement On Form S-3,2019-09-05 16:27:00-04:00,TGTX,neutral
1225917.0,Large Option Trader Sells TG Therapeutics Calls After Big Run,2019-08-12 16:52:00-04:00,TGTX,neutral
1225918.0,"TG Therapeutics Q2 EPS $(0.42) Misses $(0.41) Estimate, Sales $38K Beat $20K Estimate",2019-08-09 07:37:00-04:00,TGTX,negative
1225919.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,TGTX,negative
1225920.0,29 Healthcare Stocks Moving In Friday's After-Market Session,2019-08-02 20:51:00-04:00,TGTX,neutral
1225921.0,TG Therapeutics Highlights Presentation Of Long-Term Follow-Up Data From Phase 2 Trial Of Ublituximab In Patients With Multiple Sclerosis During An Oral Session At 5th Congress Of European Academy Of Neurology,2019-07-02 07:33:00-04:00,TGTX,neutral
1225922.0,62 Biggest Movers From Yesterday,2019-06-28 05:20:00-04:00,TGTX,neutral
1225923.0,TG Therapeutics Highlights Presentation Of Data At 15th International Conference On Malignant Lymphoma,2019-06-20 09:08:00-04:00,TGTX,neutral
1225924.0,TG Therapeutics Presents Preclinical Data for TG-1801 at the 24th European Hematology Association Annual Congress,2019-06-17 07:46:00-04:00,TGTX,neutral
1225925.0,TG Therapeutics Confirms Registration Path For Umbralisib In Marginal Zone Lymphoma Following FDA Meeting,2019-06-11 07:59:00-04:00,TGTX,neutral
1225926.0,"TG Therapeutics Reports Interim Data From UNITY-NHL Phase 2b Trial On Umbralisib Monotherapy In Patients with Marginal Zone Lymphoma Showed Overall Response Rate Of 52%, Complete Response Of 19%, Was Well Tolerated",2019-06-04 16:03:00-04:00,TGTX,positive
1225927.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,TGTX,negative
1225928.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,TGTX,neutral
1225929.0,"TG Therapeutics Q4 EPS $(0.43), Inline, Sales $38K Beat $20K Estimate",2019-05-10 07:29:00-04:00,TGTX,neutral
1225930.0,UPDATE: TG Therapeutics Says 'Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks',2019-05-07 09:04:00-04:00,TGTX,positive
1225931.0,TG Therapeutics Reports Long-Term Follow-Up Data From Phase 2 Trial Of Ublituximab In Patients Multiple Sclerosis at the American Academy of Neurology Annual Meeting,2019-05-07 09:04:00-04:00,TGTX,neutral
1225932.0,TG Therapeutics Option Alert: Jun 21 $11 Calls Sweep (23) near the Ask: 844 @ $0.3 vs 301 OI; Earnings 5/8 Before Open [est] Ref=$8.055,2019-05-03 11:09:00-04:00,TGTX,positive
1225933.0,Betaville Article Discusses Trader Speculation Of Jazz Pharmaceuticals Interest In Acquiring TG Therapeutics,2019-04-17 15:07:00-04:00,TGTX,positive
1225934.0,TG Therapeutics Option Alert: Thu $8 Calls Sweep (6) near the Ask: 500 @ $0.5 vs 10734 OI; Earnings 5/7 Before Open [est] Ref=$8.46,2019-04-17 15:01:00-04:00,TGTX,positive
1225935.0,TG Therapeutics Option Alert: May 17 $8 Calls Sweep (31) near the Ask: 568 @ $0.801 vs 1731 OI; Earnings 5/7 Before Open [est] Ref=$7.92,2019-04-17 10:55:00-04:00,TGTX,positive
1225936.0,TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the US FDAfor the Treatment of Marginal Zone Lymphoma,2019-04-15 07:35:00-04:00,TGTX,neutral
1225937.0,"TG Therapeutics Shares Volatile, Up 2.2%; Hearing Co. Receive Orphan Drug Status For Its Umbralisib",2019-04-12 10:16:00-04:00,TGTX,positive
1225938.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-04-11 08:03:00-04:00,TGTX,neutral
1225939.0,46 Stocks Moving In Monday's Mid-Day Session,2019-04-01 13:06:00-04:00,TGTX,neutral
1225940.0,TG Therapeutics shares are trading higher after the company reported positive interim trial data evaluating Umbralisib.,2019-04-01 10:14:00-04:00,TGTX,positive
1225941.0,"Benzinga Pro's Top 8 Most-Searched Tickers For Morning Of Monday, Apr. 1, 2019",2019-04-01 09:49:00-04:00,TGTX,positive
1225942.0,TG Therapeutics Highlights Presentation Of Interim Data From UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy In Patients With Marginal Zone Lymphoma At 2019 AACR Annual Meeting,2019-04-01 08:34:00-04:00,TGTX,neutral
1225943.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,TGTX,neutral
1225944.0,TGTX shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.,2019-03-29 13:45:00-04:00,TGTX,negative
1225945.0,Cantor Fitzgerald Initiates Coverage On TG Therapeutics with Overweight Rating,2019-03-29 07:05:00-04:00,TGTX,negative
1225946.0,TG Therapeutics Announces Outcome From Data Safety Monitoring Board Reviews Of UNITY-CLL And UNITY-NHL Clinical Trials; Board Identified No Safety Concerns And Recommended Trial Continue Without Modification,2019-03-08 07:32:00-05:00,TGTX,positive
1225947.0,TG Therapeutics Filing Shows Registration For 4.1M Share Common Stock Offering,2019-03-05 09:06:00-05:00,TGTX,positive
1225948.0,"TG Therapeutics Reports ~$85M In Equity, Debt Financings",2019-03-01 09:02:00-05:00,TGTX,negative
1225949.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 1, 2019",2019-03-01 08:55:00-05:00,TGTX,positive
1225950.0,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",2019-03-01 08:50:00-05:00,TGTX,neutral
1225951.0,30 Stocks Moving In Friday's Pre-Market Session,2019-03-01 08:09:00-05:00,TGTX,neutral
1225952.0,TG Therapeutics Reports Will Present Final Phase 2 Data For Multiple Sclerosis Treatment At ACTRIMS Meeting,2019-03-01 07:38:00-05:00,TGTX,neutral
1225953.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,TGTX,neutral
1225954.0,"TG Therapeutics Announces Common Stock Offering, Size Not Disclosed; Co. Also Enters Into $60M Venture Debt Financing Agreement",2019-02-28 17:05:00-05:00,TGTX,positive
1225955.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-02-28 12:28:00-05:00,TGTX,neutral
1225956.0,TG Therapeutics shares are trading higher after the company announced its UNITY-NHL phase 2b pivotal trial evaluating umbralisib met the primary endpoint of overall response rate in patients with relapsed/refractory marginal zone lymphoma.,2019-02-28 10:53:00-05:00,TGTX,positive
1225957.0,34 Stocks Moving In Thursday's Pre-Market Session,2019-02-28 08:26:00-05:00,TGTX,neutral
1225958.0,TG Therapeutics Announces UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Met Primary Endpoint OF Overall Response Rate In Patients With Relapsed/Refractory Marginal Zone Lymphoma,2019-02-28 07:25:00-05:00,TGTX,neutral
1225959.0,"TG Therapeutics Reports Initiation Of Phase I First-In-Human Trial Of TG-1801 In Patients With Relapsed, Refractory B-Cell Lymphoma",2019-02-26 07:57:00-05:00,TGTX,neutral
1225960.0,"TG Therapeutics Highlights Publication Of Data From Phase I Triple Therapy Combo Trial O""f Ublituximab, Umbralisib, Ibrutinib In 'The Lancet Haematology'",2019-01-30 07:37:00-05:00,TGTX,neutral
1225961.0,TG Therapeutics Receives Breakthrough Therapy Designation from the FDA for Umbralisib for the Treatment of Marginal Zone Lymphona,2019-01-22 07:33:00-05:00,TGTX,neutral
1225962.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,TGTX,neutral
1225963.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,TGTX,positive
1225964.0,"TG Therapeutics Offers Follow-Up Data From Triple Combo Of Ublituximab, Umbralisib, Bendamustine In Patients With DLBCL, FL At ASH",2018-12-04 07:46:00-05:00,TGTX,neutral
1225965.0,22 Stocks Moving In Monday's Pre-Market Session,2018-11-19 08:13:00-05:00,TGTX,neutral
1225966.0,"TG Therapeutics Announces Phase I Study Of Novel BTK inhibitor, TG-1701, In Patients With Relapsed Or Refractory B-cell Malignancies Is Open For Enrollment",2018-11-13 07:39:00-05:00,TGTX,positive
1225967.0,"TG Therapeutics Q3 EPS $(0.43) Beats $(0.54) Estimate, Sales $38K Beat $30K Estimate",2018-11-09 07:39:00-05:00,TGTX,neutral
1225968.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,TGTX,neutral
1225969.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,TGTX,neutral
1225970.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-22 08:05:00-04:00,TGTX,neutral
1225971.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,TGTX,positive
1225972.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,TGTX,neutral
1225973.0,5 Stocks To Have On Your Radar Next Week,2018-10-05 12:40:00-04:00,TGTX,neutral
1225974.0,"Stocks Which Set New 52-Week Low Yesterday, September 26th",2018-09-27 09:14:00-04:00,TGTX,negative
1225975.0,"Stocks Which Set New 52-Week Low Yesterday, September 25th",2018-09-26 12:44:00-04:00,TGTX,negative
1225976.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,TGTX,positive
1225977.0,51 Biggest Movers From Yesterday,2018-09-26 05:17:00-04:00,TGTX,neutral
1225978.0,Mid-Afternoon Market Update: Neogen Falls After Q1 Results; Jaguar Health Shares Surge,2018-09-25 14:42:00-04:00,TGTX,positive
1225979.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-09-25 13:06:00-04:00,TGTX,neutral
1225980.0,Mid-Day Market Update: Sonic Gains Following Acquisition News; Opiant Pharmaceuticals Shares Plummet,2018-09-25 12:45:00-04:00,TGTX,positive
1225981.0,TG Therapeutics shares are down 34.3% after an Independent Data Safety Monitoring Board advised the company that data in the UNITY-CLL trial were not mature and an overall response rate could not be completed as expected.,2018-09-25 10:58:00-04:00,TGTX,positive
1225982.0,"Raymond James Downgrades TG Therapeutics to Outperform, Lowers Price Target to $12",2018-09-25 10:52:00-04:00,TGTX,negative
1225983.0,Mid-Morning Market Update: Markets Mostly Flat; FactSet Research Misses Q4 Estimates,2018-09-25 10:17:00-04:00,TGTX,negative
1225984.0,"Hearing TG Therapeutics Downgraded at Raymond James, Unconfirmed",2018-09-25 10:03:00-04:00,TGTX,negative
1225985.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-09-25 07:40:00-04:00,TGTX,neutral
1225986.0,"TG Therapeutics Shares Resume Trade, Down 44%",2018-09-25 07:31:00-04:00,TGTX,positive
1225987.0,TG Therapeutics Shares To Resume Trade At 7:30 a.m. EDT,2018-09-25 07:06:00-04:00,TGTX,positive
1225988.0,"TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial; Independent Data Safety Monitoring Board Advised Co. That Interim Analysis Of Overall Response Rate Could Not Be Conducted, As Data Were Not Sufficiently Mature To Conduct Analysis",2018-09-25 07:03:00-04:00,TGTX,positive
1225989.0,"TG Therapeutics, Reata Pharma Shares Halted News Pending",2018-09-25 06:59:00-04:00,TGTX,positive
1225990.0,50 Biggest Movers From Yesterday,2018-09-18 06:18:00-04:00,TGTX,neutral
1225991.0,'Excellent $TGTX thread here. You've been warned.'-STAT's Adam Feuerstein Tweets,2018-09-17 13:43:00-04:00,TGTX,positive
1225992.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results",2018-08-26 15:40:00-04:00,TGTX,neutral
1225993.0,"TG Therapeutics Q2 EPS $(0.59) Misses $(0.53) Estimate, Sales $38K Beat $30K Estimate",2018-08-07 16:01:00-04:00,TGTX,negative
1225994.0,TG Therapeutics Reports Completed Target Enrollment In ULTIMATE Phase 3 Trials In Multiple Sclerosis,2018-08-07 07:40:00-04:00,TGTX,neutral
1225995.0,32 Stocks Moving In Friday's Pre-Market Session,2018-07-20 08:14:00-04:00,TGTX,neutral
1225996.0,TG Therapeutics Announces Updated Results From PHase 2 Study Of ublituximab In Patients With MS,2018-06-18 12:01:00-04:00,TGTX,neutral
1225997.0,TG Therapeutics Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy,2018-06-18 07:34:00-04:00,TGTX,negative
1225998.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,TGTX,negative
1225999.0,"TG Therapeutics Q1 EPS $(0.59) Misses $(0.44) Estimate, Sales $38K Beat $30K Estimate",2018-05-08 07:33:00-04:00,TGTX,negative
1226000.0,TG Therapeutics Offers Updated Results From Ongoing Phase 2 Study Of TG-1101 In Patients With MS: 'Data on now up to 48 patients through 24 weeks confirms previously reported positive results',2018-04-24 08:09:00-04:00,TGTX,positive
1226001.0,TG Therapeutics Option Alert: May 18 $15 Puts Sweep (24) at the Bid: 770 @ $1.301 vs 331 OI; Earnings 5/4 Before Open [est] Ref=$16.575,2018-03-13 13:44:00-04:00,TGTX,positive
1226002.0,TG Therapeutics Says Believes It Has Sufficient Cash To Operate Through Mid-2019,2018-03-08 07:32:00-05:00,TGTX,neutral
1226003.0,"TG Therapeutics Reports Q4 EPS $(0.46) vs $(0.44) Est., License Sales $38.095K vs $30K Est.",2018-03-08 07:31:00-05:00,TGTX,neutral
1226004.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-03-06 08:09:00-05:00,TGTX,neutral
1226005.0,"Jim Cramer Gives His Opinion On ConocoPhillips, Texas Instruments And More",2018-02-28 07:30:00-05:00,TGTX,neutral
1226006.0,"TG Therapeutics, Inc. Reports  Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology",2018-02-21 07:33:00-05:00,TGTX,neutral
1226007.0,Seeing Notable Block Trade In TG Therapeutics Of 1.6M Shares At $12.20/Share,2018-02-05 11:21:00-05:00,TGTX,negative
1226008.0,26 Stocks Moving In Friday's Pre-Market Session,2018-02-02 08:00:00-05:00,TGTX,neutral
1226009.0,TG Therapeutics Presented Results from Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018,2018-02-02 06:33:00-05:00,TGTX,neutral
1226010.0,TG Therapeutics Says TG-1101 Well Tolerated in Patients with MS,2018-02-02 06:32:00-05:00,TGTX,positive
1226011.0,TG Therapeutics Option Alert: Mar 16 $14 Calls Sweep (18) at the Ask: 500 @ $0.801 vs 91 OI; Earnings 3/9 Before Open [est] Ref=$12.35,2018-01-29 13:08:00-05:00,TGTX,positive
1226012.0,46 Biggest Movers From Yesterday,2018-01-12 05:25:00-05:00,TGTX,neutral
1226013.0,"TG Therapeutics, Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program, US IND Filing Expected in the First Half of 2018",2018-01-08 07:34:00-05:00,TGTX,positive
1226014.0,Seeing Notable Block Trade In TG Therapeutics; 1.8M Shares At $8.375,2017-12-27 15:59:00-05:00,TGTX,negative
1226015.0,"B. Riley Reinstates Buy on TG Therapeutics, Announces $21.50",2017-12-01 08:54:00-05:00,TGTX,neutral
1226016.0,"Benzinga's Top Upgrades, Downgrades For November 14, 2017",2017-11-14 09:13:00-05:00,TGTX,positive
1226017.0,"H.C. Wainwright Assumes TG Therapeutics at Buy, Announces price target $33.00",2017-11-14 07:14:00-05:00,TGTX,neutral
1226018.0,"TG Therapeutics Reports Q3 EPS $(0.48) vs $(0.43) Est., Sales $38K vs $30K Est.",2017-11-08 07:42:00-05:00,TGTX,neutral
1226019.0,TG Therapeutics Option Alert: May 18 $12 Calls Sweep (2) at the Bid: 500 @ $1.051 vs 2030 OI; Ref=$7.90,2017-11-01 13:16:00-04:00,TGTX,positive
1226020.0,UPDATE: TG Therapeutics Says 'TG-1101 was well tolerated across all patients including those receiving 1 hour infusions of the Phase 3 450mg dose',2017-10-27 07:31:00-04:00,TGTX,positive
1226021.0,TG Therapeutics Reports Added Updated Results From Ongoing Phase 2 Study Of TG-1101 In Patients With MS: '99% median B-cell depletion was observed at week 4 and maintained at week 24',2017-10-27 07:31:00-04:00,TGTX,neutral
1226022.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-26 08:06:00-04:00,TGTX,neutral
1226023.0,TG Therapeutics Rise 8% Premarket After Announcing Positive Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS,2017-10-26 07:52:00-04:00,TGTX,positive
1226024.0,Benzinga's Option Alert Recap From October 20,2017-10-20 16:55:00-04:00,TGTX,positive
1226025.0,TG Therapeutics Option Alert: Feb 16 $12 Calls at the Bid: 1000 @ $0.5 vs 429 OI; Ref=$7.6,2017-10-20 09:31:00-04:00,TGTX,positive
1226026.0,TG Therapeutics Shares Spike Higher Off Afternoon Lows As Hearing SunTrust Recommending Investors Buy Stock 'Aggressively',2017-10-18 14:16:00-04:00,TGTX,positive
1226027.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,TGTX,neutral
1226028.0,Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge,2017-10-16 14:30:00-04:00,TGTX,neutral
1226029.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,TGTX,neutral
1226030.0,Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline,2017-10-16 12:11:00-04:00,TGTX,positive
1226031.0,Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views,2017-10-16 10:10:00-04:00,TGTX,positive
1226032.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-16 08:17:00-04:00,TGTX,neutral
1226033.0,TG Therapeutics Says The FDA Stated GENUINE 3 Results Will Cause an Issue for Getting Accelerated Approval,2017-10-16 07:37:00-04:00,TGTX,positive
1226034.0,"TG Therapeutics Says FDA Confirmed That Accelerated Approval  Based On Overall Response Rate Would Be  A Review Issue, Also Discussed Potential Use Of Progression Free Survial From GENUINE Trial To Support Full Approval of TG-1101",2017-10-16 07:31:00-04:00,TGTX,positive
1226035.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-10-13 04:17:00-04:00,TGTX,positive
1226036.0,Benzinga's Option Alert Recap From October 12,2017-10-12 16:33:00-04:00,TGTX,positive
1226037.0,TG Therapeutics Option Alert: May 18 $18 Calls at the Bid: 500 @ $1.051 vs 0 OI; Ref=$11.35,2017-10-12 11:49:00-04:00,TGTX,positive
1226038.0,TG Therapeutics Reports Advancement Of Anti-PD-L1 Monoclonal Antibody Into Clinical Development,2017-10-05 07:34:00-04:00,TGTX,neutral
1226039.0,TG Therapeutics Reports TGR-1202 Selected For Grant From National Multiple Sclerosis Society To Support Development Of Candidate As Oral B-cell Targeted Treatment Option In Progressive MS,2017-09-29 07:31:00-04:00,TGTX,positive
1226040.0,Watch These 8 Huge Call Purchases In Thursday Trade,2017-08-24 04:07:00-04:00,TGTX,positive
1226041.0,TG Therapeutics Option Alert: Jan 19 $18 Calls Sweep (7) at the Ask: 1000 @ $0.899 vs 0 OI; Ref=$11.45,2017-08-23 10:11:00-04:00,TGTX,positive
1226042.0,"UPDATE: TG Says 'As set forth in the protocol, single agent TGR-1202 arm will be replaced with the triple combination of TG-1101, TGR-1202 and bendamustine'",2017-08-10 07:36:00-04:00,TGTX,neutral
1226043.0,UPDATE: TG Therapeutics Says DSMB 'recommends continued enrollment in the TGR-1202 + TG-1101 arm and no further enrollment into the single agent TGR-1202 arm',2017-08-10 07:36:00-04:00,TGTX,negative
1226044.0,TG Therapeutics Reports Successful Outcome From First Pre-Planned Interim Analysis By Independent DSMB Of DLBCL Cohort In UNITY-NHLPhase 2b Trial,2017-08-10 07:35:00-04:00,TGTX,positive
1226045.0,"TG Therapeutics Reports Q2 EPS $(0.45) vs $(0.43) Est., Sales $38.095K vs $40K Est.",2017-08-09 07:39:00-04:00,TGTX,neutral
1226046.0,TG Therapeutics Announces Special Protocol Assessment Agreement with the FDA for a Phase 3 Program of TG-1101 For Patients with Multiple Sclerosis,2017-08-01 07:32:00-04:00,TGTX,positive
1226047.0,TG Therapeutics Gives Update on Phase 2 Study of TG-1101,2017-06-26 07:15:00-04:00,TGTX,neutral
1226048.0,"European Hematology Association (EHA) Congress 2017 Continues Today, Bellicum Pharma Expected To Present",2017-06-23 08:22:00-04:00,TGTX,neutral
1226049.0,"European Hematology Association (EHA) Congress 2017 Begins Today, Day 1 of 4",2017-06-22 08:47:00-04:00,TGTX,neutral
1226050.0,"TG Therapeutics Recaps Positive Data from Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at #ICML2017",2017-06-16 06:24:00-04:00,TGTX,positive
1226051.0,"TG Therapeutics Announces Follow-Up Data from Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at #ICML2017",2017-06-15 04:04:00-04:00,TGTX,neutral
1226052.0,"TG Therapeutics Announces Follow-Up Data For TGR-1202, Well-Tolerated",2017-06-14 12:02:00-04:00,TGTX,neutral
1226053.0,Watch These 4 Huge Call Purchases In Wednesday Trade,2017-06-14 04:25:00-04:00,TGTX,positive
1226054.0,Option Alert: TG Therapeutics Jun 12.0 Calls Sweep: 500 @  ASK  $0.15: 596 traded vs 2152 OI:  Earnings 8/7 Before Open (est)  $11.02 Ref,2017-06-13 11:37:00-04:00,TGTX,positive
1226055.0,"TG Therapeutics Offers Follow-Up Data from Chemo-Free Triple Combo of TG-1101, TGR-1202, Ibrutinib: '100% ORR (19 of 19) observed in patients with CLL/SLL, including 32% CR rate'",2017-06-05 09:04:00-04:00,TGTX,neutral
1226056.0,25 Stocks Moving In Monday's Pre-Market Session,2017-06-05 08:07:00-04:00,TGTX,neutral
1226057.0,TG Therapeutics +8.3% Premarket @$15.00 on Light Trading; Said Phase 3  GENUINE Trial Met Primary Endpoint with TG-1101 + Ibrutinib Increasing Overall Response Rate by >70% vs Ibrutinib Alone,2017-06-05 05:13:00-04:00,TGTX,negative
1226058.0,UPDATE: TG Therapeutics Says Study Met Primary Endpoint with TG-1101 + Ibrutinib Increasing Overall Response Rate by >70% vs Ibrutinib Alone #ASCO17,2017-06-03 18:05:00-04:00,TGTX,negative
1226059.0,TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia #ASCO17,2017-06-03 18:03:00-04:00,TGTX,positive
1226060.0,TG Therapeutics Files For $300M Mixed Shelf Offering,2017-05-26 16:51:00-04:00,TGTX,neutral
1226061.0,"TG Therapeutics Reports Outcome from Pre-Planned Interim Analysis by Independent DSMB for UNITY-CLL Phase 3 Trial, Says Contribution of single Agents in Combo Regimen Successfully Established",2017-05-23 07:32:00-04:00,TGTX,positive
1226062.0,TG Therapeutics Reports Q1 EPS $(0.52) vs $(0.38) Est.,2017-05-05 07:35:00-04:00,TGTX,neutral
1226063.0,"TG Therapeutics Reports Prelim Results From Ongoing Phase 2 TG-1101 Study, Was Well Tolereated, Met Primary Endpoint",2017-04-28 08:32:00-04:00,TGTX,positive
1226064.0,Potential FDA Controversy Brewing For TG Therapeutics?,2017-04-25 11:40:00-04:00,TGTX,neutral
1226065.0,"Jefferies Initiates Coverage On TG Therapeutics with Buy Rating, Announces $23.00 Price Target",2017-04-25 10:42:00-04:00,TGTX,neutral
1226066.0,Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics,2017-04-21 10:57:00-04:00,TGTX,neutral
1226067.0,"TG Therapeutics Offers Preclinical Data for Anti-PD-L1 Monoclonal Antibody, Says First In-Human Trial Expected to Launch in '17",2017-04-04 13:03:00-04:00,TGTX,neutral
1226068.0,Don't Let Offerings Blindside Your Thesis,2017-03-19 13:51:00-04:00,TGTX,neutral
1226069.0,"TG Therapeutics Reports Q4 EPS $(0.48) vs. $(0.36) Est., Sales $38K vs. $30K Est.",2017-03-10 07:31:00-05:00,TGTX,neutral
1226070.0,TG Therapeutics Prices Offering of ~5.128M Shares at $9.75/Share,2017-03-09 09:20:00-05:00,TGTX,positive
1226071.0,"TG Therapeutics Reports Offering of Common Shares, No Terms Disclosed",2017-03-08 16:02:00-05:00,TGTX,neutral
1226072.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-03-07 08:29:00-05:00,TGTX,neutral
1226073.0,"H.C. Wainwright Reiterates Buy On TG Therapeutics, Maintains $18 Price Target",2017-03-07 07:15:00-05:00,TGTX,neutral
1226074.0,Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher,2017-03-06 14:33:00-05:00,TGTX,positive
1226075.0,"SunTrust Comments on TG Therapeutics Following Phase 3 GENUINE Study Results: Sees Approval for TG-1101, Raises Price Target to $26",2017-03-06 13:32:00-05:00,TGTX,positive
1226076.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,TGTX,neutral
1226077.0,Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher,2017-03-06 12:18:00-05:00,TGTX,positive
1226078.0,Hearing FBR Raises Price Target For TG Therapeutics To $26/Share,2017-03-06 12:15:00-05:00,TGTX,neutral
1226079.0,Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital,2017-03-06 10:07:00-05:00,TGTX,negative
1226080.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,TGTX,neutral
1226081.0,"TGTX Resumes Trade, Up Over 30.8% After Hours At $8.70",2017-03-06 07:32:00-05:00,TGTX,neutral
1226082.0,TG Therapeutics to Resume Trading at 7:30 AM ET,2017-03-06 07:14:00-05:00,TGTX,neutral
1226083.0,UPDATE: TG Therapeutics Says GENUINE Study Of TG-1101 Was Well Tolerated With Consistent Safety Profile With Phase 2 Study Of ublituximab Plus ibrutinib,2017-03-06 07:04:00-05:00,TGTX,positive
1226084.0,TG Therapeutics Phase 3 GENUINE Study Meets Primary Endpoint,2017-03-06 07:02:00-05:00,TGTX,neutral
1226085.0,TG Therapeutics and Concert Pharma Halted,2017-03-06 06:59:00-05:00,TGTX,neutral
1226086.0,"Aegis Capital Initiates Coverage On TG Therapeutics at Buy, Announces $26.00 Target",2017-02-22 08:53:00-05:00,TGTX,neutral
1226087.0,"TG Therapeutics Reports orphan Drug Designation for Combo of TG-1101, TGR-1202 for Treatment of Diffuse Large B-cell Lymphoma",2017-01-24 07:30:00-05:00,TGTX,neutral
1226088.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-11 12:35:00-05:00,TGTX,neutral
1226089.0,TG Therapeutics Surrenders Early Gains After Positive Multiple Sclerosis Study Data,2017-01-11 12:22:00-05:00,TGTX,positive
1226090.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-01-11 08:22:00-05:00,TGTX,neutral
1226091.0,TG Therapeutics +18% Premarket @$5.90; Co Announced Positive MS Study Data,2017-01-11 07:48:00-05:00,TGTX,positive
1226092.0,TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 in Treatment of Chronic Lymphocytic Leukemia,2017-01-09 07:31:00-05:00,TGTX,neutral
1226093.0,TG Therapeutics Investigator Initiated Study of TGR-1202,2017-01-04 07:31:00-05:00,TGTX,neutral
1226094.0,"TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101",2016-12-16 09:31:00-05:00,TGTX,neutral
1226095.0,"TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment, Top-Line Data Expected First Half 2017",2016-12-06 07:01:00-05:00,TGTX,positive
1226096.0,"TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib in Patients with Relapsed, Refractory CLL, MCL Showed Combo is Well Tolerated with No Grade 3/4 Transaminitis, Pneumonitis, Diarrhea, Colitis Observed",2016-12-05 11:16:00-05:00,TGTX,neutral
1226097.0,TG Therapeutics Up 2.5+% PreMarket; Earlier Announced Positive DSMB Recommendation for Continuation of Unity-CLL Phase 3 Trial,2016-11-22 08:26:00-05:00,TGTX,positive
1226098.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-07 08:34:00-05:00,TGTX,neutral
1226099.0,"TG Therapeutics Reports Q3 Net Loss $24.8M vs $13.7M in Same Qtr. Last Year, EPS $(0.50) vs $(0.31) Est.",2016-11-07 07:37:00-05:00,TGTX,negative
1226100.0,"TG Therapeutics, Inc. Reports Publication in Blood Describing a Novel Complimentary Mechanism of the PI3K-delta Inhibitor, TGR-1202",2016-10-27 07:39:00-04:00,TGTX,positive
1226101.0,Ladenburg Thalmann Positive On TG Therapeutics Post Adjustments To GENUINE Study,2016-10-14 11:17:00-04:00,TGTX,positive
1226102.0,TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track,2016-10-14 11:11:00-04:00,TGTX,negative
1226103.0,15 Biggest Mid-Day Losers For Thursday,2016-10-13 13:08:00-04:00,TGTX,negative
1226104.0,Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates,2016-10-13 10:03:00-04:00,TGTX,positive
1226105.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-13 08:48:00-04:00,TGTX,neutral
1226106.0,"TG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial, Revising Primary Endpoint to Overall Response Rate",2016-10-13 07:05:00-04:00,TGTX,neutral
1226107.0,TG Therapeutics Has Quite The Promising Pipeline,2016-10-06 13:26:00-04:00,TGTX,positive
1226108.0,"Brean Capital Assumes TG Therapeutics at Buy, Announces $28.00 PT",2016-10-06 05:40:00-04:00,TGTX,neutral
1226109.0,TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder,2016-08-26 08:00:00-04:00,TGTX,negative
1226110.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-24 12:56:00-04:00,TGTX,neutral
1226111.0,TG Therapeutics Reports Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia,2016-08-24 09:26:00-04:00,TGTX,neutral
1226112.0,A Handful of Biotech Stocks Plunge After Disappointing Results,2016-08-08 16:51:00-04:00,TGTX,negative
1226113.0,12 Biggest Mid-Day Losers For Monday,2016-08-08 13:07:00-04:00,TGTX,negative
1226114.0,TG Therapeutics Reports Q2 EPS $(0.33) vs. Est. $(0.29),2016-08-08 07:32:00-04:00,TGTX,neutral
1226115.0,Stocks Hitting 52-Week Lows,2016-07-18 10:35:00-04:00,TGTX,negative
1226116.0,"TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib, Recaps Long-Term Safety, Efficacy Data of TGR-1202 in CLL, NHLs",2016-06-10 09:16:00-04:00,TGTX,positive
1226117.0,TG Therapeutics Reports First Patient Enrolled in Registration-Directed UNITY-DLBCL Phase 2b Trial,2016-06-07 07:31:00-04:00,TGTX,neutral
1226118.0,TG Therapeutics Reports TGR-1202 Shows High Response Rates And Differentiated & Favorable Safety Profile,2016-06-06 09:01:00-04:00,TGTX,positive
1226119.0,Benzinga's Top Initiations,2016-05-27 09:29:00-04:00,TGTX,positive
1226120.0,TG Therapeutics Strikes Global Alliance To Develop Novel BET Inhibitors For Hematological Malignancies Treatment,2016-05-27 09:00:00-04:00,TGTX,negative
1226121.0,The Market In 5 Minutes: Happy Memorial Day Weekend,2016-05-27 08:52:00-04:00,TGTX,positive
1226122.0,"TG Therapeutics Enters Global Partnership To Develop, Commercialize Novel BET Inhibitors Developed By Jubilant Biosys For Hematological Malignancy Treatments; Receives Upfront Licensing Fee Of $1M & Potential Milestones Of ~$177M",2016-05-27 07:31:00-04:00,TGTX,positive
1226123.0,SunTrust Robinson Humphrey Initiates Coverage on TG Therapeutics at Buy,2016-05-27 07:30:00-04:00,TGTX,neutral
1226124.0,"TG Therapeutics Reports Q1 EPS $(0.28) vs $(0.36) Est., License Sales $38.1K vs $30K Est.",2016-05-10 16:29:00-04:00,TGTX,neutral
1226125.0,TG Therapeutics Reports Launch of First Clinical Trial in MS for TG-1101,2016-05-03 07:36:00-04:00,TGTX,neutral
1226126.0,TG Therapeutics To Present Pre-Clinical Data At American Association For Cancer Research Annual Meeting,2016-04-18 08:53:00-04:00,TGTX,negative
1226127.0,"TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States",2016-04-13 07:30:00-04:00,TGTX,positive
1226128.0,"TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Meeting",2016-03-17 07:31:00-04:00,TGTX,negative
1226129.0,TG Therapeutics Plans Launchof  First Phase 2 Trial In MS for TG-1101 Next 30-60 Days,2016-03-07 16:02:00-05:00,TGTX,neutral
1226130.0,"TG Therapeutics  Reports Q4 EPS $(0.37)Vs Est $(0.32), Sales $38.095K Vs Est $40.0K",2016-03-07 16:01:00-05:00,TGTX,neutral
1226131.0,"Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp",2016-01-24 19:56:00-05:00,TGTX,neutral
1226132.0,"TG Therapeutics +11.46% @$8.85; Co Presenting at J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 9:00 PST",2016-01-12 09:49:00-05:00,TGTX,neutral
1226133.0,"Roth Capital Reiterates Buy & 'Focus List' Status On TG Therapeutics, Sees Co. 'positioning itself strongly'",2015-12-07 13:09:00-05:00,TGTX,positive
1226134.0,"TG Therapeutics, Inc. Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University",2015-12-07 11:30:00-05:00,TGTX,positive
1226135.0,"TG Therapeutics Announces Data Presentations from Ongoing Clinical Studies in Patients With NHL, CLL at #ASH2015",2015-12-06 18:57:00-05:00,TGTX,neutral
1226136.0,"FBR Capital Earlier Initiated Coverage on TG Therapeutics at Outperform, Announced $29.00 PT",2015-12-01 10:32:00-05:00,TGTX,neutral
1226137.0,"TG Therapeutics Reports Q3 EPS $(0.28) vs. Est. $(0.34), Rev. $38.096K vs. Est. $40K",2015-11-09 07:32:00-05:00,TGTX,neutral
1226138.0,13G Filing from Bridger Mgmt on TG Therapeutics Shows New 6% Stake,2015-10-05 16:43:00-04:00,TGTX,neutral
1226139.0,Mid-Morning Market Update: Markets Mostly Flat; Rite Aid Earnings Miss Views,2015-09-17 10:35:00-04:00,TGTX,negative
1226140.0,Morning Market Gainers,2015-09-17 09:42:00-04:00,TGTX,neutral
1226141.0,TG Therapeutics Announces Special Protocol Assessment Agreement With the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 in Combination With TGR-1202 for Patients With Chronic Lymphocytic Leukemia,2015-09-17 07:39:00-04:00,TGTX,positive
1226142.0,"TG Therapeutics, Inc. Launches Phase 1/2 ""Triple-Therapy"" Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) at the University of Pennsylvania's Abramson Cancer Center",2015-09-09 08:32:00-04:00,TGTX,negative
1226143.0,TG Therapeutics: A Buy Worth $22,2015-08-12 07:46:00-04:00,TGTX,positive
1226144.0,"H.C. Wainwright Assumes TG Therapeutics at Buy, Announces $22.00 PT",2015-08-12 07:07:00-04:00,TGTX,neutral
1226145.0,TG THerapeutics Reports Q2 Loss $0.38 Vs Est Loss $0.30,2015-08-10 07:31:00-04:00,TGTX,negative
1226146.0,"New Results From Phase 2 Clinical Trial of TG-1101 in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety  in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia",2015-06-18 11:16:00-04:00,TGTX,positive
1226147.0,TG Therapeutics to Present Clinical Data on TG-1101 and TGR-1202 at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma,2015-06-11 16:31:00-04:00,TGTX,neutral
1226148.0,Tedegar Increase Dividend To $0.11 From $0.09,2015-06-04 14:05:00-04:00,TGTX,positive
1226149.0,What's Happening At The ASCO Conference?,2015-06-03 10:08:00-04:00,TGTX,neutral
1226150.0,"TG Therapeutics Announces the Triple Combination of TG-1101, TGR-1202 and Ibrutinib is Safe and Highly Active in Patients With Advanced B-Cell Malignancies",2015-06-01 11:00:00-04:00,TGTX,positive
1226151.0,TG Therapeutics Presents Proprietary Combination of TG-1101 Plus TGR-1202 as Well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Clinical Studies,2015-05-31 12:42:00-04:00,TGTX,positive
1226152.0,"TG Therapeutics Reports Q1 GAAP Loss of of $0.39/Share, May Not Compare to Loss of $0.33/Share",2015-05-04 17:25:00-04:00,TGTX,negative
1226153.0,TG Therapeutics Reports Q1 EPS Loss $0.36 Vs Est Loss $0.33,2015-05-04 17:02:00-04:00,TGTX,negative
1226154.0,Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds,2015-04-20 07:41:00-04:00,TGTX,positive
1226155.0,"TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting",2015-04-20 07:31:00-04:00,TGTX,negative
1226156.0,TG Therapeutics Reports Q4 EPS $(0.48) vs. Est. $(0.26),2015-03-11 17:05:00-04:00,TGTX,neutral
1226157.0,"TG Therapeutics Reports Global Collaboration with Checkpoint Therapeutics for Development, Commercialization of Novel Immuno-Oncology Targeted Antibodies",2015-03-04 08:34:00-05:00,TGTX,positive
1226158.0,"Coronado Biosciences Forms Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies",2015-03-04 08:33:00-05:00,TGTX,positive
1226159.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,TGTX,neutral
1226160.0,TG Therapeutics Shares Spike to High,2015-01-05 09:58:00-05:00,TGTX,positive
1226161.0,The Top 5 Biotech Gainers Of 2014,2014-12-29 14:15:00-05:00,TGTX,positive
1226162.0,TG Therapeutics Announces Preliminary Results From Ongoing Phase I/II Dose Escalation Study of TG-1101,2014-12-09 11:12:00-05:00,TGTX,neutral
1226163.0,"TG Therapeutics Reports Data from Phase 2 Trial of TG-1101, Ibrutinib Show 'Compelling Clinical Activity in Patients with Previously Treated, High-Risk CLL",2014-12-08 13:46:00-05:00,TGTX,positive
1226164.0,TG Therapeutics Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib For Patients With Select B-Cell Malignancies,2014-12-01 08:31:00-05:00,TGTX,neutral
1226165.0,Wainwright Sees TG Therapeutics As Take-Out Target,2014-10-27 13:20:00-04:00,TGTX,neutral
1226166.0,UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside,2014-10-27 08:19:00-04:00,TGTX,positive
1226167.0,"H.C. Wainwright Initiates Coverage on TG THERAPEUTICS INC at Buy, Announces $17.00 PT",2014-10-27 07:05:00-04:00,TGTX,neutral
1226168.0,13G Filing from RA Capital Mgmt on TG Therapeutics Shows New 8.3% Stake,2014-10-17 16:26:00-04:00,TGTX,neutral
1226169.0,"TG Therapeutics Announces Exercise of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202",2014-09-23 07:31:00-04:00,TGTX,positive
1226170.0,US Stock Futures Down Ahead Of Industrial Production Report,2014-09-15 07:13:00-04:00,TGTX,neutral
1226171.0,TG Therapeutics Announces Special Protocol Assessment Agreement With The FDA for Its First Phase 3 Clinical Trial of TG-1101 In Combination With ImbruvicaF or Patients With Previously Treated Chronic Lymphocytic Leukemia,2014-09-15 07:06:00-04:00,TGTX,positive
1226172.0,"TG Therapeutics Reports Novel 'Chemo-Free' Triple Therapy Combo Study for Patients with Chronic Lymphocytic Leukemia, Other B-Cell Malignancies",2014-08-15 07:31:00-04:00,TGTX,positive
1226173.0,TG Therapeutics Spikes to High on Volume,2014-08-07 10:40:00-04:00,TGTX,neutral
1226174.0,TG Therapeutics' Novel Combination of TG-1101 and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas ,2014-07-21 16:16:00-04:00,TGTX,positive
1226175.0,TG THERAPEUTICS INC Reports Q4 EPS of $(0.36) vs $(0.24) Est,2014-07-21 16:08:00-04:00,TGTX,neutral
1226176.0,UPDATE: MLV & Co. Reiterates On TG Therapeutics On Multiple Positive Factors,2014-07-02 09:54:00-04:00,TGTX,positive
1226177.0,Benzinga's Volume Movers,2014-06-24 10:41:00-04:00,TGTX,neutral
1226178.0,TG Therapeutics Completes Licensing Agreement With Ligand Pharma to Develop Inhibitors of IRAK4,2014-06-24 08:10:00-04:00,TGTX,positive
1226179.0,Ligand Signs License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program,2014-06-24 05:49:00-04:00,TGTX,positive
1226180.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,TGTX,neutral
1226181.0,Morning Market Losers ,2014-06-13 09:44:00-04:00,TGTX,negative
1226182.0,US Stock Futures Fall Ahead Of Consumer Sentiment Report,2014-06-13 07:14:00-04:00,TGTX,neutral
1226183.0,TG Therapeutics' TG-1101 in Combination With Ibrutinib Shows 90% Response Rate in Patients With Previously Treated  CLL and MCL,2014-06-13 05:33:00-04:00,TGTX,neutral
1226184.0,"Mid-Day Market Movers For Thursday, June 12, 2014",2014-06-12 13:05:00-04:00,TGTX,neutral
1226185.0,TG Therapeutics Announces Will Present Highlighted Data from TGR-1202 Data,2014-05-30 13:56:00-04:00,TGTX,neutral
1226186.0,TG THERAPEUTICS INC Reports Q1 EPS of $(0.25) vs $(0.19) Est; Reaffirms Outlook,2014-05-12 16:33:00-04:00,TGTX,neutral
1226187.0,TG Therapeutics Provides Update on a Modified TGR-1202 Formulation and Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure ,2014-05-08 08:34:00-04:00,TGTX,neutral
1226188.0,TG Therapeutics Reports Sale of 2.7M Shares at $6.71/Share,2014-03-11 17:14:00-04:00,TGTX,positive
1226189.0,TG THERAPEUTICS INC Reports Q4 EPS of $(0.19) vs $(0.18) Est,2014-03-05 16:01:00-05:00,TGTX,neutral
1226190.0,"TG Therapeutics Says TGR-1202 Appears Well Tolerated, Grade 3 Events Have Been Limited",2013-12-09 11:13:00-05:00,TGTX,positive
1226191.0,TG Therapeutics Presents Encouraging TGR-1202 Data at ASH,2013-12-09 10:58:00-05:00,TGTX,positive
1226192.0,TG Therapeutics Target Boosted from $8 to $12 at Ladenburg Thalmann,2013-11-25 12:57:00-05:00,TGTX,positive
1226193.0,TG THERAPEUTICS INC Reports Q3 EPS of $(0.16) vs $(0.22) Est,2013-11-11 16:30:00-05:00,TGTX,neutral
1226194.0,Benzinga's Top Initiations,2013-11-06 08:53:00-05:00,TGTX,positive
1226195.0,"MLV & Co. Initiates Coverage on TG THERAPEUTICS INC at Buy, Announces $9.00 PT",2013-11-05 18:39:00-05:00,TGTX,neutral
1226196.0,"TG Therapeutics' Ublituximab Wins Orphan Drug Status for Treatment of NMZL, EMZL",2013-09-09 07:32:00-04:00,TGTX,positive
1226197.0,Shares of TG Therapeutics Move Up 3% Following Added Orphan Drug Status from FDA,2013-09-06 15:10:00-04:00,TGTX,positive
1226198.0,"TG Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Of 5.7 Million Shares At $6.15 per Share",2013-07-18 08:44:00-04:00,TGTX,positive
1226199.0,TG Therapeutics Approved for Listing on the NASDAQ Capital Market,2013-05-28 08:31:00-04:00,TGTX,positive
1226200.0,"Benzinga's Microcap Movers for Thursday November 8, 2012",2012-11-08 22:06:00-05:00,TGTX,neutral
